Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 11/20 | 0.46 |
| ▸ | JAK3 | P52333 | 5/20 | 0.46 |
| ▸ | JAK1 | P23458 | 6/20 | 0.44 |
| ▸ | PTK2 | Q05397 | 3/20 | 0.42 |
| ▸ | FLT3 | P36888 | 1/20 | 0.40 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.39 |
| ▸ | TYK2 | P29597 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3303547 | 0.90 | JAK2 (0.62) | JAK2JAK3JAK1PTK2FLT3 | |
| SCHEMBL13390968 | 0.88 | MAPK8 (0.43) | JAK2JAK3JAK1PTK2 | |
| SCHEMBL13391401 | 0.78 | JAK2 (0.47) | JAK2JAK3JAK1PTK2 | |
| SCHEMBL3303894 | 0.77 | JAK1 (0.59) | JAK2JAK3JAK1PTK2 | |
| SCHEMBL3305387 | 0.72 | JAK2 (0.52) | JAK2JAK3JAK1PTK2 | |
| SCHEMBL13391239 | 0.72 | GRM4 (0.40) | JAK2JAK3PTK2FLT3GRM4 | |
| SCHEMBL26967715 | 0.72 | DYRK1A (0.52) | FLT3 | |
| SCHEMBL2144173 | 0.70 | JAK2 (0.49) | JAK2JAK3JAK1PTK2FLT3 | |
| SCHEMBL2144612 | 0.69 | JAK2 (0.48) | JAK2JAK3JAK1PTK2 | |
| SCHEMBL2144880 | 0.69 | PDPK1 (0.39) | JAK2JAK3PTK2FLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12516043-B2 | Stiripentol derivative and use thereof | NATIONAL UNIVERSITY CORPORATION OKAYAMA UNIVERSITY (JP) | 2026-01-06 | — | — | US | disclosed |
| US-20230303543-A1 | NOVEL STIRIPENTOL DERIVATIVE AND USE THEREOF | NATIONAL UNIVERSITY CORPORATION OKAYAMA UNIVERSITY (JP) | 2023-09-28 | — | — | US | disclosed |
| EP-4190401-A1 | NOVEL STIRIPENTOL DERIVATIVE AND USE THEREOF | National University Corporation Okayama University (JP) | 2023-06-07 | — | — | EP | disclosed |
| EP-2344494-B1 | AMINOTRIAZOLOPYRIDINES AND THEIR USE AS KINASE INHIBITORS | SIGNAL PHARM LLC (US) | 2016-04-20 | — | — | EP | disclosed |
| US-20130005707-A1 | AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | BAHMANYAR SOGOLE (US) | 2013-01-03 | — | — | US | disclosed |
| US-8299056-B2 | Aminotriazolopyridines, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2012-10-30 | — | — | US | disclosed |
| US-20100093698-A1 | AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARMACEUTICALS, LLC | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130005707-A1 | AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | MAP3K2, MAP3K1, MAP3K3 | JAK2 26/4885JAK3 86/4885JAK1 69/4885 |
| US-20100093698-A1 | AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | MAP3K2, MAP3K1, MAP3K3 | JAK2 26/4885JAK3 86/4885JAK1 69/4885 |
| US-20230303543-A1 | NOVEL STIRIPENTOL DERIVATIVE AND USE THEREOF | LDHA, SDHA, LDHB | JAK2 3093/4885JAK3 4694/4885JAK1 4655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.